The creation of consistent and high value engagements with individuals across their digital and in-person engagements will enable these providers to both attract and retain consumers in the rapidly evolving healthcare ecosystem.
Tapping into community pharmacy can bring water to these rural healthcare deserts. Studies show that nine in ten Americans live within five miles of a pharmacy and high-risk patients visited their community pharmacy an average of 35 times per year, compared to four visits to their primary care provider and nine visits to specialists.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The largest six pharmacy benefit managers are being scrutinized by the Federal Trade Commission, while Congress is debating the Pharmacy Benefit Transparency Act. Meanwhile, states have their own ideas for reining in what they see as excesses of the industry. With all this heat, what is the message from the head of the Pharmaceutical Care Management Association?
As healthcare organizations comply with the federal EPCS mandate, artificial intelligence and digital identity technologies should be utilized to detect, reduce, and remediate drug diversion.
Health plans today must consider what they want out of their pharmacy benefits and how to achieve something better for their members. And when they look at new platforms and processes that provide greater transparency, improved member experience, and simplicity in establishing and maintaining the technology, they’re likely to find that they don’t have to do things the way they always have.
Transcarent wants to transform the digital pharmacy benefit experience, enabling self-insured employers and their staff to make more informed choices.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Requiring that PBMs bid on a per member per month guarantee would reduce the employer’s uncertainty by securing the actual per member per month cost to the employer.
The question elicited predictable and unexpected responses from panelists that included a senior executive from CVS Caremark and executives from startup companies working to change the pharmacy benefits landscape.
When pharmacies engage on a human level with patient support programs, patients become more fully engaged in their treatment, leading to potentially significant health benefits and good business for pharmacies.
At the upcoming INVEST Digital Health conference in Dallas set for September 28, in collaboration with Health Wildcatters, a panel discussion on the future of pharmacy benefit managers will be part of the larger conversation on employee benefits. AJ Loiacono, CapitalRx CEO, shared his perspective on the topic.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
RxBenefits, a pharmacy benefits optimizer, and Tria Health, a chronic condition and medication management company, have launched a new partnership to improve diabetes care and lower healthcare costs for the condition through a proactive approach.
As life science companies seek to boost clinical trial participation, eConsent forms can pose a stumbling block. A white paper by Medable shares some insights on how companies can leverage eConsent to improve clinical trial recruitment and retention.
Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.
A study published in the Journal of Managed Care + Specialty Pharmacy found Medicare Advantage patients reduced their cost of care by using specialty pharmacies instead of mail order or retail pharmacies.
Pharmacy benefit managers have been widely criticized for opaque drug pricing practices. But Waltz Health, which was co-founded by former PBM executive Mark Thierer, aims to use insider knowledge and tech solutions to lower drug costs.